Janus Henderson Group
CLVS

Janus Henderson Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Janus Henderson Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,347
Closed -$42K – 2731
2022
Q1 		$42K Buy
20,347
+77
+0.4% +$151 ﹤0.01% 2624
2021
Q4 		$55K Buy
20,270
+10,239
+102% +$37.8K ﹤0.01% 2536
2021
Q3 		$45K Buy
+10,031
New +$48.3K ﹤0.01% 2179
2018
Q1 		– Sell
-7,385
Closed -$502K – 1398
2017
Q4 		$502K Sell
7,385
-177,826
-96% -$12.4M ﹤0.01% 1222
2017
Q3 		$15.3M Sell
185,211
-31,994
-15% -$2.54M 0.01% 793
2017
Q2 		$20.3M Buy
+217,205
New +$13.3M 0.01% 740

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Janus Henderson Group's CLVS Position: Q2 2022 in Review

Janus Henderson Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 20,347 shares — an estimated $42K sold.

Janus Henderson Group first reported a position in CLVS in Q2 2017 and held it in 6 quarters. The position peaked at $20.3M in Q2 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • Janus Henderson Group reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • Janus Henderson Group sold 20,347 Clovis Oncology, Inc. shares in Q2 2022, an estimated $42K.
  • Janus Henderson Group first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 6 quarters.
  • Janus Henderson Group's Clovis Oncology, Inc. position peaked at $20.3M in Q2 2017.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Janus Henderson Group's 13F filing for Q2 2022, filed 15 Aug 2022.